Crown Marketing Files Provisional Patent Application for Diet Supplement
30 Mayo 2013 - 6:36AM
Marketwired
Crown Marketing (OTCQB: CWNM) is pleased to
announce that it has filed a provisional patent application with
the United States Patent and Trademark Office for a unique and
novel dietary supplement.
After researching the most recent developments and studies in
nutritional and dietary formulations, Crown believes it has
developed a supplement with benefits and efficacy superior to
currently available supplements.
Under the America Invents Act (AIA), the U.S. patent laws were
amended in ways that represent the biggest changes in decades to
U.S. patent law. The most significant changes of the AIA are
effective March 16, 2013 and have forever altered the way U.S.
patents will be offensively and defensively used in the supplement
industry.
The AIA contains many groundbreaking changes to U.S. patent law
that will impact the supplement industry for years to come. We
believe these changes provide a unique opportunity for Crown to
gain a competitive advantage over others who do not incorporate
these new changes into their intellectual property strategies.
About Crown Nutraceuticals:
Crown Nutraceuticals is engaged in the development,
manufacturing and marketing of popular nutraceuticals and
supplements.
The global nutraceuticals product market is massive -- reaching
over $142.1 billion in 2011 and the industry is projected to reach
$204.8 billion by 2017, with a projected annual growth rate of 6.3%
from 2012 to 2017. Asia Pacific (including Japan) is expected to
have the second largest market share after North America by 2017.
Crown's objective is to rapidly expand its business in the
nutraceuticals and supplement market.
About Crown Marketing:
Crown Marketing's Controlled Drug Delivery
Technology (CDDT) holds patents for a novel controlled-release
technology, harnessing the principles of chaos theory along with
precise mathematical formulas for precise and programmable
diffusion delivery.
The spectrum and reliability of pharmacokinetic profiles
achievable with this technology is superior to currently marketed
formulations. Its simple design allows for a high level of
flexibility in matching chrono-therapeutic requirements. Cost
efficiencies in the commercial manufacturing process, when compared
to other drug delivery technologies, may constitute its most
important competitive advantage.
The objective of intelligent drug delivery design amounts to
maximizing the percent of the time drug plasma levels are within
the therapeutic range and avoiding patient exposure to potentially
toxic (High) or sub-therapeutic (Low) levels.
Crown's cost-effective application of controlled delivery
technologies will play a major role in the expansion of the
pharmaceutical, OTC and nutraceuticals industry through our ability
to improve on the performance of immediate release products in a
manner tangible to manufacturers and consumers.
More information can be found at: www.crowncddt.com
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that
projected or suggested herein due to certain risks and
uncertainties including, without limitation, ability to obtain
financing and regulatory and shareholder approvals for anticipated
actions.
Contact: Charles Van Der Ross 347-491-0565
America Great Health (CE) (USOTC:AAGH)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
America Great Health (CE) (USOTC:AAGH)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025